• LAST PRICE
    0.5701
  • TODAY'S CHANGE (%)
    Trending Down-0.0050 (-0.8694%)
  • Bid / Lots
    0.5701/ 3
  • Ask / Lots
    0.5750/ 6
  • Open / Previous Close
    0.5717 / 0.5751
  • Day Range
    Low 0.5701
    High 0.5858
  • 52 Week Range
    Low 0.5528
    High 2.5300
  • Volume
    61,474
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 0.5753
TimeVolumeBLRX
09:32 ET52690.58
09:34 ET10840.575
09:39 ET27660.572
09:48 ET1000.5858
09:54 ET10000.585799
09:57 ET3000.58
10:08 ET1670.5848
10:14 ET3000.5725
10:15 ET9000.584
10:17 ET1000.573
10:19 ET1000.573
10:24 ET1000.573
10:28 ET112970.5725
10:32 ET1000.5725
10:33 ET10000.575
10:35 ET23000.5725
10:37 ET20000.575
10:39 ET1000.5725
10:44 ET112760.5725
10:48 ET2240.5817
10:51 ET36380.572
10:53 ET1540.573499
10:57 ET93800.571
11:00 ET18500.5702
11:04 ET6000.5701
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBLRX
BioLine RX Ltd
52.8M
-0.7x
---
United StatesKRON
Kronos Bio Inc
56.8M
-0.5x
---
United StatesLVTX
LAVA Therapeutics NV
51.0M
-1.8x
---
United StatesKZR
Kezar Life Sciences Inc
47.8M
-0.5x
---
United StatesDYAI
Dyadic International Inc
45.3M
-6.2x
---
United StatesMRKR
Marker Therapeutics Inc
41.4M
-3.5x
---
As of 2024-06-26

Company Information

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Contact Information

Headquarters
Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
Phone
---
Fax
---

Executives

Chairman of the Board
Aharon Schwartz
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Vice President - Development
Ella Sorani
Vice President-Clinical & Medical Affairs
Abi Vainstein-Haras

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$52.8M
Revenue (TTM)
$11.7M
Shares Outstanding
79.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.51
EPS
$-0.76
Book Value
$0.18
P/E Ratio
-0.7x
Price/Sales (TTM)
4.5
Price/Cash Flow (TTM)
---
Operating Margin
-391.76%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.